Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 281 to 290 of 543 total matches.

Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
— Avutometinib is a dual rapid accelerated fibrosarcoma (RAF)/mitogen-activated kinase (MEK) 1 inhibitor. RAF ...
Avmapki Fakzynja Co-Pack (Verastem), a combination of the kinase inhibitors avutometinib and defactinib, has received accelerated approval from the FDA for treatment of KRAS-mutated recurrent low-grade serous ovarian cancer in women who had previously received systemic therapy. Neither drug is approved for use as monotherapy for any indication. Avmapki Fakzynja is the first treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e120-1   doi:10.58347/tml.2025.1733j |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
ER caps with alcohol can result in rapid release of morphine Maximum dose of multiphase ER caps ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Advice for Travelers

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019  (Issue 1582)
ascent with a slow increase in sleeping elevation. Acetazolamide is recommended when rapid ascent ...
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-60 |  Show IntroductionHide Introduction

Table: Treatments Considered for COVID-19 (Archived) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
on these drugs is evolving rapidly and The Medical Letter does not warrant that all the material ...
View the Table: Treatments Considered for COVID-19
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289 |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
for all stages of AD dementia. Pharmacokinetics – Oral donepezil is rapidly absorbed from the GI tract; plasma ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Microx

   
The Medical Letter on Drugs and Therapeutics • Jun 17, 1988  (Issue 768)
rapidly and more completely than other formulations of metolazone. Serum concentrations reach a peak ...
Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls hypertension with less potassium loss, making it safer than other diuretics and as effective as combination drugs, such as Dyazide, that include both a thiazide and a potassium-sparing diuretic. Medical Letter consultants generally do not recommend Dyazide or other fixed-dose combinations for treatment of hypertension.
Med Lett Drugs Ther. 1988 Jun 17;30(768):63-4 |  Show IntroductionHide Introduction

Terconazole For Candida Vaginitis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
of terconazole is absorbed systemically; the drug is rapidly metabolized by the liver and excreted in urine ...
Terconazole (Terazol - Ortho), an imidazole derivative, was recently marketed in the USA for treatment of vulvovaginal candidiasis. It is available both as a 0.4% vaginal cream (Terazol 7) and in 80-mg vaginal suppositories (Terazol 3).
Med Lett Drugs Ther. 1988 Dec 30;30(782):118-9 |  Show IntroductionHide Introduction

Astemizole - Another Non-Sedating Anthistamine

   
The Medical Letter on Drugs and Therapeutics • May 05, 1989  (Issue 792)
-adrenergic receptors. PHARMACOKINETICS — Astemizole is rapidly absorbed from the gastrointestinal tract ...
Astemizole (Hismanal - Janssen), a new antihistamine, was recently marketed in the USA for treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Like terfenadine (Seldane - Medical Letter, 27:65, 1985), astemizole is claimed to be no more sedating than placebo, but the new drug offers the advantage of a once-daily dosage schedule.
Med Lett Drugs Ther. 1989 May 5;31(792):43-4 |  Show IntroductionHide Introduction

Nitroglycerin Patches - Do They Work?

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
patches rapidly become ineffective for treatment of angina pectoris if they are left in place for 24 ...
Transdermal nitroglycerin products commercially available in the USA are listed in the table below. These patches, which look like adhesive bandages, are often applied over the precordium, but they can be attached to any hairless area of the skin, except distal parts of the extremities. Individual patients vary in their absorption of nitroglycerin from the skin; the amounts delivered (the doses) are average figures.
Med Lett Drugs Ther. 1989 Jul 14;31(796):65-6 |  Show IntroductionHide Introduction

Octreotide - A Synthetic Somatostatin

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
, abstract 370). IV octreotide has rapidly reversed, and prior subcutaneous injection has prevented, life ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Med Lett Drugs Ther. 1989 Jul 14;31(796):66-8 |  Show IntroductionHide Introduction